Abstract: Secukinumab is a recombinant human monoclonal antibody targeting interleukin-17A (IL-17A), currently approved for the treatment of moderate to severe psoriasis. Although it exhibits good safety and tolerance, there are still reports of inducing multiple autoimmune diseases during the use of secukinumab, such as systemic lupus erythematosus and bullous pemphigoid. This article reports a case of bullous pemphigoid that occurred during the treatment of severe plaque psoriasis with secukinumab.

Key words: secukinumab, bullous pemphigoid, psoriasis